TrialPanorama/Dataset huggingface dataset:
Please select the outcome measures that correspond to the clinical trial below.
Title: Trial of Vitamins Among Children of HIV-infected Women
Brief Summary: The purpose of this study is to examine the effects of multivitamin (B, C, E) supplementation on reducing the risk of morbidity and mortality outcomes among children born to HIV positive mothers, compared to placebo supplementation.


Options:
A: All-cause mortality and diarrheal morbidity (age 6 weeks to age 24 months)
B: Percent true calcium absorption (After 6 months of treatment)
C: Number of children dying during the study period; Average weight gain in each of the treatment groups
D: Vitamin D plasma concentrations (12 months)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Trial of Vitamins Among Children of HIV-infected Women
Brief Summary: The purpose of this study is to examine the effects of multivitamin (B, C, E) supplementation on reducing the risk of morbidity and mortality outcomes among children born to HIV positive mothers, compared to placebo supplementation.


Options:
A: Incidence of diarrhea (from ages 6 weeks to 18 months); respiratory tract infections (from ages 6 weeks to 18 months)
B: Plasma zinc concentration (3 weeks)
C: All-cause mortality and diarrheal morbidity (age 6 weeks to age 24 months)
D: To evaluate innate and adaptive immune response.; Future occurrence of acute diarrhoea, ARI and impetigo.

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Trial of Vitamins Among Children of HIV-infected Women
Brief Summary: The purpose of this study is to examine the effects of multivitamin (B, C, E) supplementation on reducing the risk of morbidity and mortality outcomes among children born to HIV positive mothers, compared to placebo supplementation.


Options:
A: Number of Participants with D- deficiency or access (at 40 (+/-2 weeks) PMA (postmenstrual age)); Number of Participants with D- deficiency or access (at 4 weeks of age); Number of Participants with D- deficiency or access (At 35 (+/-2 weeks) PMA (postmenstrual age)); Number of Participants with D- deficiency or access (At 52 (+/-2 weeks) PMA (postmenstrual age))
B: All-cause mortality and diarrheal morbidity (age 6 weeks to age 24 months)
C: Change in CD4 percent associated with vitamin D supplementation in HIV-infected children (6 months)
D: Blood 25 Hydroxyvitamin D (25OHD) Concentrations (1 day (On admission to the pediatric intensive care unit (PICU) following CHD surgery))

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Vitamins, Breastmilk HIV Shedding, and Child Health
Brief Summary: The purpose of this study is to analyze stored samples and data collected during the conduct of the study "A Trial of Vitamins in HIV Progression and Transmission" (HD32257). The aims are to examine the effect of vitamin supplementation on HIV infected women during pregnancy on a number of parameters in breastmilk.


Options:
A: Low birthweight (< 2500 g) (Delivery); Pre-term birth (< 36 weeks gestation) (Monthly until the 32nd week of pregnancy, once every 2 weeks from 32nd to 36th week)
B: Pregnancy-related mortality and all cause mortality (Continuous)
C: Birth weight; 3-month infant mortality
D: cell-free viral load and/or cell-associated proviral load in breast milk (Delivery, 3 months, and 6 months after delivery); concentration of vitamins A, B12, and E in breast milk (Delivery, 3 months, and 6 months post-delivery); subclinical mastitis (Delivery, 3 months, and 6 months after delivery)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Novel Pharmacological Strategies in Autism
Brief Summary: This study will determine the effectiveness of aripiprazole and D-Cycloserine in treating symptoms associated with autism in children.


Options:
A: Mean Post-baseline Aberrant Behavior Checklist Irritability Score, Parent Report, Double-blind Phase (Weeks 1, 2, 3, 4, 6, and 8); Odds of Improvement as Measured by the Clinical Global Impression-Global Improvement Scale (Improvement Defined as CGI-I=1 or CGI-I=2) (Weeks 1, 2, 3, 4, 6 and 8)
B: Clinical Global Impressions Scale - Improvement - Social (6 Weeks); Repetitive Behavior Scale - Revised (6 Weeks); Diagnostic Analysis of Nonverbal Accuracy, Paralanguage Test (6 Weeks)
C: Aberrant Behavior Checklist- 2nd Edition (ABC-2): Irritability subscale raw score (Baseline to Week 12)
D: Aberrant Behavior Checklist Hyperactivity Subscale (Week 8)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Novel Pharmacological Strategies in Autism
Brief Summary: This study will determine the effectiveness of aripiprazole and D-Cycloserine in treating symptoms associated with autism in children.


Options:
A: Clinical Global Improvement (Week 12)
B: Percentage of Participants Who Were Attention Deficit Hyperactivity Disorder (ADHD) Respondents (week 10); Percentage of Participants Who Were Autism Spectrum Disorder Respondents (week 10)
C: Rate of Recruitment (19 months)
D: Mean Post-baseline Aberrant Behavior Checklist Irritability Score, Parent Report, Double-blind Phase (Weeks 1, 2, 3, 4, 6, and 8); Odds of Improvement as Measured by the Clinical Global Impression-Global Improvement Scale (Improvement Defined as CGI-I=1 or CGI-I=2) (Weeks 1, 2, 3, 4, 6 and 8)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Novel Pharmacological Strategies in Autism
Brief Summary: This study will determine the effectiveness of aripiprazole and D-Cycloserine in treating symptoms associated with autism in children.


Options:
A: Aberrant Behavior Checklist - Social Withdrawal Subscale (Phase 1 - Week 4 and 12, Phase 2 - Week 4 and 8)
B: Mean Conners' Teacher ADHD Index T Score by Dose (Measured at each dosing week of the drug trial (placebo, low, medium, high)); Mean Continuous Performance Test (CPT)-Commission Errors by Dose (Measured at each dosing week of the drug trial (placebo, low, medium, high))
C: Mean Post-baseline Aberrant Behavior Checklist Irritability Score, Parent Report, Double-blind Phase (Weeks 1, 2, 3, 4, 6, and 8); Odds of Improvement as Measured by the Clinical Global Impression-Global Improvement Scale (Improvement Defined as CGI-I=1 or CGI-I=2) (Weeks 1, 2, 3, 4, 6 and 8)
D: Core autistic symptoms (ATEC) (Once every 4 weeks during the first three mounth); Side effects and adverse events questionnaire (Once every 4 weeks during the first phase(12 weeks))

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: A Randomized Controlled Trial of D-Cycloserine in Autism
Brief Summary: This study will determine the effectiveness of D-cycloserine in reducing symptoms of autism in autistic children.


Options:
A: Aberrant Behavior Checklist - Social Withdrawal Subscale (Phase 1 - Week 4 and 12, Phase 2 - Week 4 and 8)
B: Clinical Global Impression -- Improvement (CGI-I) Scale (Weekly for 4 weeks, then monthly, with 16-week end point. Primary outcome assessment used two time points, baseline and 16 weeks.); Clinical Global Impression -- Severity (CGI-S) Scale (Baseline, 8 weeks, and 16 weeks. Primary outcome assessment used 2 time points, baseline and 16 weeks.)
C: Change in Clinical Global Impressions (CGI) Global Improvement (Change from Baseline at 8 Weeks); Change in Clinical Global Impressions (CGI) Global Improvement (Change from Open-Label Baseline at 8 Weeks); Change in Lethargy Subscale of the Aberrant Behavior Checklist (ABC) (Change from Baseline at 8 Weeks.); Change in Lethargy Subscale of the Aberrant Behavior Checklist (ABC) (Change from Open-Label Baseline at 8 Weeks)
D: Number of Participants Reporting Improvement on the Clinical Global Impression (Baseline to end of study (week 15)); Change in Aberrant Behaviors as Measured by the Aberrant Behavior Checklist Scores (Baseline and End of Study (week 15))

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: A Randomized Controlled Trial of D-Cycloserine in Autism
Brief Summary: This study will determine the effectiveness of D-cycloserine in reducing symptoms of autism in autistic children.


Options:
A: Core autistic symptoms (ATEC) (Once every 4 weeks during the first three mounth); Side effects and adverse events questionnaire (Once every 4 weeks during the first phase(12 weeks))
B: Change in Clinical Global Impressions (CGI) Global Improvement (Change from Baseline at 8 Weeks); Change in Clinical Global Impressions (CGI) Global Improvement (Change from Open-Label Baseline at 8 Weeks); Change in Lethargy Subscale of the Aberrant Behavior Checklist (ABC) (Change from Baseline at 8 Weeks.); Change in Lethargy Subscale of the Aberrant Behavior Checklist (ABC) (Change from Open-Label Baseline at 8 Weeks)
C: Change From Baseline in Brain Activity During Task (Task-based fMRI) After a Single Dose of Nasal Spray (Value at 30 minutes minus value at baseline); Change From Baseline in Brain Activity During Task (Task-based fMRI) After 4 Weeks of Nasal Spray (Value at 4 weeks minus value at baseline); Change From Baseline in Brain Activity During Task (Task-based fMRI) After 8 Weeks, Including 4 Weeks Without Nasal Spray (Value at 8 weeks minus value at baseline); Change From Baseline in Brain Activity During Task (Task-based fMRI) After 52 Weeks, Including 48 Weeks Without Nasal Spray (Value at 52 weeks minus value at baseline); Change From Baseline in Brain Connectivity During Rest (Resting-state fMRI) After a Single Dose of Nasal Spray (Value at 30 minutes minus value at baseline); Change From Baseline in Brain Connectivity During Rest (Resting-state fMRI) After 4 Weeks of Nasal Spray (Value at 4 weeks minus value at baseline); Change From Baseline in Brain Connectivity During Rest (Resting-state fMRI) After 8 Weeks, Including 4 Weeks Without Nasal Spray (Value at 8 weeks minus value at baseline); Change From Baseline in Brain Connectivity During Rest (Resting-state fMRI) After 52 Weeks, Including 48 Weeks Without Nasal Spray (Value at 52 weeks minus value at baseline)
D: Mean Post-baseline Aberrant Behavior Checklist Irritability Score, Parent Report, Double-blind Phase (Weeks 1, 2, 3, 4, 6, and 8); Odds of Improvement as Measured by the Clinical Global Impression-Global Improvement Scale (Improvement Defined as CGI-I=1 or CGI-I=2) (Weeks 1, 2, 3, 4, 6 and 8)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: A Randomized Controlled Trial of D-Cycloserine in Autism
Brief Summary: This study will determine the effectiveness of D-cycloserine in reducing symptoms of autism in autistic children.


Options:
A: Change in Clinical Global Impressions (CGI) Global Improvement (Change from Baseline at 8 Weeks); Change in Clinical Global Impressions (CGI) Global Improvement (Change from Open-Label Baseline at 8 Weeks); Change in Lethargy Subscale of the Aberrant Behavior Checklist (ABC) (Change from Baseline at 8 Weeks.); Change in Lethargy Subscale of the Aberrant Behavior Checklist (ABC) (Change from Open-Label Baseline at 8 Weeks)
B: Proportion of Patients Meeting the Criterion for Loss of Therapeutic Response (LTR) by the End of the Study (Based on Observed Cases) (Baseline (Visit 1) to week 12)
C: Aberrant Behavior Checklist - Social Withdrawal Subscale (Phase 1 - Week 4 and 12, Phase 2 - Week 4 and 8)
D: The primary measure will be a global composite derived by calculating the z scores on each measure other than CGI from published norms (or from the baseline descriptives, then averaging the z scores of the various outcome measures for each individual. (Baseline, weeks 2, 4, 6, 8, 10,12, and 14.)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: A Randomized Controlled Trial of D-Cycloserine in Autism
Brief Summary: This study will determine the effectiveness of D-cycloserine in reducing symptoms of autism in autistic children.


Options:
A: Clinical Global Impression-Improvement Scale (CGI-I) (Baseline to 12 weeks)
B: Social Responsiveness Scale (SRS) Change (Completed at Baseline and Week 11); Social Responsiveness Scale (SRS) at Follow-Up (Completed at Week 22)
C: Treatment Responder (12 Weeks (from Baseline [Week 0] to Endpoint [Week 12]))
D: Change in Clinical Global Impressions (CGI) Global Improvement (Change from Baseline at 8 Weeks); Change in Clinical Global Impressions (CGI) Global Improvement (Change from Open-Label Baseline at 8 Weeks); Change in Lethargy Subscale of the Aberrant Behavior Checklist (ABC) (Change from Baseline at 8 Weeks.); Change in Lethargy Subscale of the Aberrant Behavior Checklist (ABC) (Change from Open-Label Baseline at 8 Weeks)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Etiology, Prevention, and Treatment of Neonatal Infections in the Community
Brief Summary: The purpose of this study is to determine what are the major types of bacteria that cause newborn infections in the community in rural Bangladesh and whether providing an obstetric and neonatal care package will reduce neonatal deaths by 40%.


Options:
A: Post day 1 Neonatal mortality (birth to 28 days of age) in the communities receiving the intervention(cohort of infants born to women identified through pregnancy surveillance) (Over 30 Months); Neonatal mortality (from birth to 28 days of age) in the cohort identified through pregnancy surveillance (Over 30 Months); Post day 1 neonatal mortality (1 to 28 days of age) in the population of newborns who are more likely to have greater impact from the intervention i.e. those born at home and available in the study area within 7 days of birth (30 months); Neonatal mortality (from birth to 28 days of age) in the population more likely to benefit from the intervention (30 months); Infant mortality (birth to 365 days) in the communities receiving the intervention. (30 months)
B: All cause Neonatal Mortality (2 years)
C: Health workers will visit households at three month intervals for 18 months and survey the status of the babies.
D: Neonatal mortality rate (deaths within 28 days of birth)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Etiology, Prevention, and Treatment of Neonatal Infections in the Community
Brief Summary: The purpose of this study is to determine what are the major types of bacteria that cause newborn infections in the community in rural Bangladesh and whether providing an obstetric and neonatal care package will reduce neonatal deaths by 40%.


Options:
A: the number and spacing of subsequent pregnancies and births (When first child is 12); the rates of marriage and cohabitation with the father of the child (When first child is 12); mothers' employment, career growth, economic self-sufficiency, and welfare dependence (When first child is 12); mothers' behavioral problems due to substance abuse (When first child is 12); children's academic achievement, placements in special education, rates of grade retention, conduct in school, and academic achievement (At age 12); rates of developmental disability, grade retention, placement in special education, and school disciplinary actions among subsequent children (At age 12); mothers' arrests for serious misdemeanors and felonies (When first child is 12)
B: Skilled delivery attendance (From inclusion to 42 days after delivery. Asssessed at delivery and confirmed 42 days after delivery)
C: Proportion of infants born to HIV-infected mothers who have acquired HIV (During the first 2 years of life); Proportion of HIV-exposed infants tested for HIV (During the first 2 years of life); Proportion of pregnant women making at least four antenatal clinic visits (Between the first week of gestation and delivery); Proportion of pregnant women delivering at a healthcare facility (At delivery); Proportion of HIV-positive women receiving PMTCT (Between the first antenatal care visit and 1 week after stopping breastfeeding)
D: Health workers will visit households at three month intervals for 18 months and survey the status of the babies.

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Etiology, Prevention, and Treatment of Neonatal Infections in the Community
Brief Summary: The purpose of this study is to determine what are the major types of bacteria that cause newborn infections in the community in rural Bangladesh and whether providing an obstetric and neonatal care package will reduce neonatal deaths by 40%.


Options:
A: Placental malaria (After delivery)
B: N/A
C: Perinatal mortality (12 months)
D: Health workers will visit households at three month intervals for 18 months and survey the status of the babies.

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Newborn Thermal Care Practices in Rural India: A Community Based Program to Prevent and Improve Recognition and Management of Hypothermia
Brief Summary: The purpose of this study is to train mothers/caretakers on how to prevent their babies from becoming too cold.


Options:
A: To evaluate in a community based controlled effectiveness trial whether addition of zinc as a therapeutic modality for diarrhea delivered through existing channels, including at village level to the current case management package for under-five children (20 months (Jan 2005 to Sep 2006)); - Reduction in visits to health care providers for treatment of illness (20 months (Jan 2005 to Sep 2006)); - Reduction in drug use; antibiotics and other drugs during diarrheal illnesses (20 months (Jan 2005 to Sep 2006)); - Increase in ORS use during diarrhea in the intervention communities. (20 months (Jan 2005 to Sep 2006))
B: N/A
C: N/A
D: Neonatal mortality rate

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Newborn Thermal Care Practices in Rural India: A Community Based Program to Prevent and Improve Recognition and Management of Hypothermia
Brief Summary: The purpose of this study is to train mothers/caretakers on how to prevent their babies from becoming too cold.


Options:
A: Newborn survival (to 28 days) (July 2010 to June 2013)
B: N/A
C: Treatment failure (Seven days)
D: Complications detected (3 days after delivery); Successful referrals (10 days after delivery (survey and administrative records)); Care Seeking Behavior around complications and well baby check-up (10 days after delivery (survey)); Knowledge of danger signs (10 days after delivery (survey)); Breastfeeding (10 days and 9 weeks after delivery (survey))

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Newborn Thermal Care Practices in Rural India: A Community Based Program to Prevent and Improve Recognition and Management of Hypothermia
Brief Summary: The purpose of this study is to train mothers/caretakers on how to prevent their babies from becoming too cold.


Options:
A: HIV-related transmission acts (18 months); Baby's health status (18 months); Maternal adherence to HIV-related and general health routines (18 months); Mental health (18 months); Social support (18 months)
B: Newborn survival (to 28 days) (July 2010 to June 2013)
C: the number and spacing of subsequent pregnancies and births (When first child is 12); the rates of marriage and cohabitation with the father of the child (When first child is 12); mothers' employment, career growth, economic self-sufficiency, and welfare dependence (When first child is 12); mothers' behavioral problems due to substance abuse (When first child is 12); children's academic achievement, placements in special education, rates of grade retention, conduct in school, and academic achievement (At age 12); rates of developmental disability, grade retention, placement in special education, and school disciplinary actions among subsequent children (At age 12); mothers' arrests for serious misdemeanors and felonies (When first child is 12)
D: N/A

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Newborn Thermal Care Practices in Rural India: A Community Based Program to Prevent and Improve Recognition and Management of Hypothermia
Brief Summary: The purpose of this study is to train mothers/caretakers on how to prevent their babies from becoming too cold.


Options:
A: Placental malaria (After delivery)
B: N/A
C: Post day 1 Neonatal mortality (birth to 28 days of age) in the communities receiving the intervention(cohort of infants born to women identified through pregnancy surveillance) (Over 30 Months); Neonatal mortality (from birth to 28 days of age) in the cohort identified through pregnancy surveillance (Over 30 Months); Post day 1 neonatal mortality (1 to 28 days of age) in the population of newborns who are more likely to have greater impact from the intervention i.e. those born at home and available in the study area within 7 days of birth (30 months); Neonatal mortality (from birth to 28 days of age) in the population more likely to benefit from the intervention (30 months); Infant mortality (birth to 365 days) in the communities receiving the intervention. (30 months)
D: Baby's health status (6 days after birth; 6 months after birth; 12 months after birth)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Newborn Thermal Care Practices in Rural India: A Community Based Program to Prevent and Improve Recognition and Management of Hypothermia
Brief Summary: The purpose of this study is to train mothers/caretakers on how to prevent their babies from becoming too cold.


Options:
A: N/A
B: neonatal mortality; umbilical cord infection
C: Incidence of Neonatal Omphalitis (By the end of the styudy); Rate of Neonatal Mortality (By the end of the Study)
D: Neonatal death or severe sepsis (7 days)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Newborn Thermal Care Practices in Rural India: A Community Based Program to Prevent and Improve Recognition and Management of Hypothermia
Brief Summary: The purpose of this study is to train mothers/caretakers on how to prevent their babies from becoming too cold.


Options:
A: Axillary temperature 36.5-37.5 degrees Celsius (1-4 hours)
B: Death to discharge or at six months corrected gestational age (discharge or six months corrected gestational age)
C: Axillary temperature taken on admission to the NICU (immediately after cap and wrap removal) and again 1 hour later. (Admission to the NICU)
D: N/A

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Community Based Interventions to Reduce Neonatal Mortality in Bangladesh
Brief Summary: This project delivers, promotes and facilitates services related to pregnancy, delivery and newborn care.


Options:
A: Incidence of diarrhea (weekly)
B: Neonatal mortality rate
C: N/A
D: To evaluate in a community based controlled effectiveness trial whether addition of zinc as a therapeutic modality for diarrhea delivered through existing channels, including at village level to the current case management package for under-five children (20 months (Jan 2005 to Sep 2006)); - Reduction in visits to health care providers for treatment of illness (20 months (Jan 2005 to Sep 2006)); - Reduction in drug use; antibiotics and other drugs during diarrheal illnesses (20 months (Jan 2005 to Sep 2006)); - Increase in ORS use during diarrhea in the intervention communities. (20 months (Jan 2005 to Sep 2006))

Answer: B